GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpha Tau Medical Ltd (NAS:DRTS) » Definitions » Buyback Yield %

DRTS (Alpha Tau Medical) Buyback Yield % : 0.00 (As of Mar. 31, 2025)


View and export this data going back to 2022. Start your Free Trial

What is Alpha Tau Medical Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Alpha Tau Medical's current buyback yield was 0.00%.


Alpha Tau Medical Buyback Yield % Historical Data

The historical data trend for Alpha Tau Medical's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpha Tau Medical Buyback Yield % Chart

Alpha Tau Medical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Buyback Yield %
Get a 7-Day Free Trial - - - - -

Alpha Tau Medical Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alpha Tau Medical's Buyback Yield %

For the Biotechnology subindustry, Alpha Tau Medical's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alpha Tau Medical's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alpha Tau Medical's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Alpha Tau Medical's Buyback Yield % falls into.


;
;

Alpha Tau Medical Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Alpha Tau Medical's Buyback Yield for the fiscal year that ended in Dec. 2024 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 218.1811
=0.00%

Alpha Tau Medical's annualized Buyback Yield for the quarter that ended in Dec. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 218.1811
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .


Alpha Tau Medical Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Alpha Tau Medical's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alpha Tau Medical Business Description

Traded in Other Exchanges
N/A
Address
Kiryat Hamada Street 5, Jerusalem, ISR, 9777605
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.